Immunobiological therapy: psoriasis, Stelara (ustekinumab), personalized approach and safety — Radeski Skin Clinic.
What is immunobiological therapy?
Despite many systemic options for psoriasis, 40–50% of patients stop treatment due to insufficient effect, intolerance, or adverse reactions.
Patients with moderate to severe psoriasis, comorbidities, and significant allergy history need personalized systemic therapy.
Why modern biologics?
Methotrexate and similar agents with cytostatic and teratogenic effects should be limited in women of reproductive age planning pregnancy. Genetically engineered biologics with a safer profile are preferred.
Stelara (ustekinumab)
The gold standard of biologic therapy is Stelara, used in dermatology for more than 10 years.
Ustekinumab binds the p40 subunit of inflammatory interleukins IL-12 and IL-23, blocking receptor interaction.
Clinical outcomes
- Joint tropism — effective in psoriatic arthritis.
- After the fourth injection, nail dystrophy signs may improve.
- PSOLAR registry: ~87% of 12,000+ patients continued ustekinumab at 4 years.
Stelara maintains strong long-term effectiveness in real-world practice.
At Radeski Clinic
Leading dermatologists at Radeski Skin & Aesthetic Clinic have extensive experience prescribing immunobiological therapy for psoriasis, atopic dermatitis, urticaria, hidradenitis suppurativa, and Darier disease.
Related services: Immunobiological therapy, Psoriasis school, Prices.
Who is immunobiological therapy for?
Moderate to severe psoriasis, psoriatic arthritis, and other immune-mediated conditions under physician supervision.
How fast does Stelara work?
Individual. Some signs improve within weeks; nail changes may improve after several injections.
Is it safe in pregnancy?
The plan is discussed individually with your physician. Biologics are evaluated separately from methotrexate.